Ocean Biomedical, Inc. is a biopharmaceutical company focused on bridging the bench-to-bedside gap by licensing inventions from research universities and medical centers to develop therapeutic products for diseases with significant unmet medical needs. The company leverages its relationships with Brown University and Rhode Island Hospital to advance a diversified pipeline of preclinical product candidates in oncology, fibrosis, and infectious diseases. Its business model…
Ocean Biomedical, Inc. is a biopharmaceutical company focused on bridging the bench-to-bedside gap by licensing inventions from research universities and medical centers to develop therapeutic products for diseases with significant unmet medical needs. The company leverages its relationships with Brown University and Rhode Island Hospital to advance a diversified pipeline of preclinical product candidates in oncology, fibrosis, and infectious diseases. Its business model emphasizes operational efficiency, milestone-driven development, and strategic partnerships to maximize value creation across its portfolio.
Ocean Biomedical generates revenue through the development and potential commercialization of its licensed product candidates, primarily via internal advancement, partnerships with established pharmaceutical companies, spin-outs, or initial public offerings. The company does not currently have commercial products on the market and relies on future milestones such as IND filings, clinical trial progress, and potential regulatory approvals to create value. Revenue is expected to arise from milestone payments, royalties, and equity stakes in subsidiaries housing its therapeutic programs.
The company operates through the following segments: Oncology, Fibrosis, and Infectious Diseases.
- Oncology: This segment focuses on developing therapeutic candidates targeting chitinase 3-like-1 (Chi3l1) for the treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). The segment includes product candidates such as OCX-253, a monospecific monoclonal antibody against Chi3l1; OCX-410, a bispecific antibody targeting Chi3l1 and PD-1; and OCX-909, a bispecific antibody targeting Chi3l1 and CTLA-4. These candidates are designed to modulate oncogenic pathways and enhance immune response, with preclinical data showing significant tumor reduction in animal models.
- Fibrosis: This segment is dedicated to advancing OCF-203, a small molecule therapeutic candidate targeting chitinase 1 (Chit1) for the treatment of idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak syndrome (HPS). OCF-203 aims to inhibit fibrosis by modulating the transforming growth factor beta 1 pathway, with preclinical studies demonstrating reduced fibrotic markers in animal models of IPF and HPS. The segment addresses a significant unmet need, particularly for HPS, which currently lacks approved pharmacological therapies.
- Infectious Diseases: This segment centers on malaria therapeutic and vaccine candidates based on the antigens PfSEA-1 and PfGARP, discovered using the Whole Proteome Differential Screening (WPDS) platform developed by Dr. Jonathan Kurtis. The segment includes ODA-570, a malaria vaccine candidate; ODA-611, a humanized monoclonal antibody against PfGARP; and ODA-579, a small molecule inhibitor of PfGARP. These candidates aim to prevent and treat symptomatic Plasmodium falciparum infection, with preclinical data showing potent parasite-killing activity and protection in non-human primate models.
Ocean Biomedical occupies a niche position in the biopharmaceutical industry as a translator of academic discoveries into therapeutic candidates, differentiating itself from traditional biotech firms by focusing exclusively on in-licensing early-stage innovations from research institutions. Its competitive advantage lies in its subsidiary-based structure, which allows it to offer meaningful equity stakes to academic partners, aligning incentives and enhancing access to high-potential technologies. The company faces competition from larger pharmaceutical firms and venture-backed biotechs seeking similar academic partnerships, but believes its agile, milestone-driven model and diversified pipeline provide resilience against reliance on any single program.
Ocean Biomedical serves patients suffering from oncology, fibrosis, and infectious diseases, with a focus on individuals with non-small cell lung cancer, glioblastoma, idiopathic pulmonary fibrosis, Hermansky-Pudlak syndrome, and malaria. The company collaborates with research institutions such as Brown University and Rhode Island Hospital, which serve as the source of its licensed technologies and scientific expertise.